HUE031559T2 - Eljárás angiogenezis, vaszkularizáció vagy érjavítás elõsegítésére vagy tumor-angiogenezis gátlására - Google Patents
Eljárás angiogenezis, vaszkularizáció vagy érjavítás elõsegítésére vagy tumor-angiogenezis gátlására Download PDFInfo
- Publication number
- HUE031559T2 HUE031559T2 HUE08844273A HUE08844273A HUE031559T2 HU E031559 T2 HUE031559 T2 HU E031559T2 HU E08844273 A HUE08844273 A HU E08844273A HU E08844273 A HUE08844273 A HU E08844273A HU E031559 T2 HUE031559 T2 HU E031559T2
- Authority
- HU
- Hungary
- Prior art keywords
- kot
- angiogenesis
- rti
- ség ség
- ség
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 9
- 230000033115 angiogenesis Effects 0.000 title description 12
- 230000008439 repair process Effects 0.000 title description 4
- 230000005764 inhibitory process Effects 0.000 title description 2
- 230000002792 vascular Effects 0.000 title description 2
- 230000005747 tumor angiogenesis Effects 0.000 title 1
- 239000004575 stone Substances 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 241001067739 Lotis Species 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 210000005070 sphincter Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 12
- 230000012010 growth Effects 0.000 description 4
- 108091059456 miR-92-1 stem-loop Proteins 0.000 description 4
- 108091084336 miR-92-2 stem-loop Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- GSJBKPNSLRKRNR-UHFFFAOYSA-N $l^{2}-stannanylidenetin Chemical compound [Sn].[Sn] GSJBKPNSLRKRNR-UHFFFAOYSA-N 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101100012466 Drosophila melanogaster Sras gene Proteins 0.000 description 1
- 241001245789 Goodea atripinnis Species 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001120822 Homo sapiens Putative microRNA 17 host gene protein Proteins 0.000 description 1
- 108010016766 KK 3 Proteins 0.000 description 1
- 241000252067 Megalops atlanticus Species 0.000 description 1
- 101100380295 Mus musculus Asah1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000083652 Osca Species 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000932075 Priacanthus hamrur Species 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 102100026055 Putative microRNA 17 host gene protein Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710144764 Suppressor of SWI4 1 homolog Proteins 0.000 description 1
- 102100029338 Suppressor of SWI4 1 homolog Human genes 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- -1 aerolites Substances 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000027746 artery morphogenesis Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229920006245 ethylene-butyl acrylate Polymers 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 235000000396 iron Nutrition 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007052114A DE102007052114B4 (de) | 2007-10-30 | 2007-10-30 | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE031559T2 true HUE031559T2 (hu) | 2017-07-28 |
Family
ID=40375407
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13179144A HUE037494T2 (hu) | 2007-10-30 | 2008-10-30 | Eljárás angiogenezis, vaszkularizáció vagy érjavítás elõsegítésére, vagy tumor-angiogenezis gátlására |
| HUE08844273A HUE031559T2 (hu) | 2007-10-30 | 2008-10-30 | Eljárás angiogenezis, vaszkularizáció vagy érjavítás elõsegítésére vagy tumor-angiogenezis gátlására |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13179144A HUE037494T2 (hu) | 2007-10-30 | 2008-10-30 | Eljárás angiogenezis, vaszkularizáció vagy érjavítás elõsegítésére, vagy tumor-angiogenezis gátlására |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8258113B2 (enExample) |
| EP (3) | EP2684956B1 (enExample) |
| JP (4) | JP5898843B2 (enExample) |
| CA (1) | CA2704290C (enExample) |
| CY (2) | CY1120360T1 (enExample) |
| DE (1) | DE102007052114B4 (enExample) |
| DK (2) | DK2684955T3 (enExample) |
| ES (2) | ES2651287T3 (enExample) |
| HR (2) | HRP20170346T1 (enExample) |
| HU (2) | HUE037494T2 (enExample) |
| LT (2) | LT2684955T (enExample) |
| NO (1) | NO2684955T3 (enExample) |
| PL (2) | PL2217704T3 (enExample) |
| PT (2) | PT2684955T (enExample) |
| SI (2) | SI2217704T1 (enExample) |
| WO (1) | WO2009056116A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| HUE037173T2 (hu) | 2006-08-08 | 2018-08-28 | Univ Bonn Rheinische Friedrich Wilhelms | 5'-Foszfát-oligonukleotidok szerkezete és alkalmazása |
| DE102007052114B4 (de) | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
| US9738680B2 (en) | 2008-05-21 | 2017-08-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5′ triphosphate oligonucleotide with blunt end and uses thereof |
| US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
| US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
| WO2012065024A1 (en) * | 2010-11-11 | 2012-05-18 | University Of Miami | Compositions, cells, kits and methods for autologous stem cell therapy |
| EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
| US9884076B2 (en) | 2012-06-05 | 2018-02-06 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
| CN104685056A (zh) | 2012-06-21 | 2015-06-03 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| EP2882445B1 (en) | 2012-08-13 | 2019-04-24 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
| EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
| EP2759595B1 (en) * | 2013-01-24 | 2016-09-14 | Pierre Fabre Médicament S.A.S. | Composition comprising an encapsulated antagomir |
| WO2014145356A1 (en) | 2013-03-15 | 2014-09-18 | MiRagen Therapeutics, Inc. | Bridged bicyclic nucleosides |
| US11253549B2 (en) | 2014-05-23 | 2022-02-22 | JangoBio, LLC | Methods to rebalance the hypothalamic-pituitary-gonadal axis |
| US11439668B2 (en) | 2014-05-23 | 2022-09-13 | JangoBio, LLC | Methods to differentiate stem cells into hormone-producing cells |
| CA2962444C (en) | 2014-10-03 | 2023-09-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| US20160122762A1 (en) * | 2014-10-27 | 2016-05-05 | University Of Iowa Research Foundation | Methods of treating atherosclerosis |
| HK1249108A1 (zh) * | 2015-01-20 | 2018-10-26 | 米拉根医疗股份有限公司 | Mir-92抑制剂及其用途 |
| WO2017123662A1 (en) | 2016-01-11 | 2017-07-20 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
| CN107586784B (zh) * | 2016-07-08 | 2020-08-25 | 田小利 | 一种分离的rnasek基因及其在制备抗血管衰老药物中的应用 |
| EP3515459A4 (en) | 2016-09-20 | 2020-08-05 | Cedars-Sinai Medical Center | CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS |
| US11759482B2 (en) | 2017-04-19 | 2023-09-19 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| EP3749344A4 (en) | 2018-02-05 | 2022-01-26 | Cedars-Sinai Medical Center | METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS |
| WO2019167995A1 (ja) * | 2018-02-28 | 2019-09-06 | 国立大学法人東京医科歯科大学 | 虚血病変部位特異的な遺伝子治療法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648914A4 (en) * | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| AU2005250432B2 (en) * | 2004-05-28 | 2011-09-15 | Asuragen, Inc. | Methods and compositions involving microRNA |
| EP1904111A4 (en) * | 2005-06-03 | 2009-08-19 | Univ Johns Hopkins | COMPOSITIONS AND METHODS FOR REDUCING MICRORNA EXPRESSION FOR THE TREATMENT OF NEOPLASIA |
| EP2455492B1 (en) * | 2006-07-13 | 2013-11-20 | The Ohio State University Research Foundation | Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases |
| US8466117B2 (en) * | 2006-07-28 | 2013-06-18 | The Johns Hopkins University | Compositions and methods for modulating angiogenesis |
| WO2008070082A2 (en) * | 2006-12-04 | 2008-06-12 | The Johns Hopkins University | Stem-progenitor cell specific micro-ribonucleic acids and uses thereof |
| WO2009004632A2 (en) * | 2007-07-05 | 2009-01-08 | Yeda Research And Development Co. Ltd. | Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation |
| WO2009012468A2 (en) * | 2007-07-18 | 2009-01-22 | The Regents Of The University Colorado | Differential expression of micrornas in nonfailing versus failing human hearts |
| DE102007052114B4 (de) | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
-
2007
- 2007-10-30 DE DE102007052114A patent/DE102007052114B4/de active Active
-
2008
- 2008-10-30 PT PT131791444T patent/PT2684955T/pt unknown
- 2008-10-30 ES ES13179144.4T patent/ES2651287T3/es active Active
- 2008-10-30 NO NO13179144A patent/NO2684955T3/no unknown
- 2008-10-30 US US12/739,876 patent/US8258113B2/en active Active
- 2008-10-30 EP EP13179146.9A patent/EP2684956B1/de active Active
- 2008-10-30 EP EP08844273.6A patent/EP2217704B1/de active Active
- 2008-10-30 CA CA2704290A patent/CA2704290C/en not_active Expired - Fee Related
- 2008-10-30 PL PL08844273T patent/PL2217704T3/pl unknown
- 2008-10-30 PT PT88442736T patent/PT2217704T/pt unknown
- 2008-10-30 JP JP2010531412A patent/JP5898843B2/ja not_active Expired - Fee Related
- 2008-10-30 WO PCT/DE2008/001759 patent/WO2009056116A1/de not_active Ceased
- 2008-10-30 PL PL13179144T patent/PL2684955T3/pl unknown
- 2008-10-30 DK DK13179144.4T patent/DK2684955T3/en active
- 2008-10-30 DK DK08844273.6T patent/DK2217704T3/en active
- 2008-10-30 HU HUE13179144A patent/HUE037494T2/hu unknown
- 2008-10-30 EP EP13179144.4A patent/EP2684955B1/de active Active
- 2008-10-30 HR HRP20170346TT patent/HRP20170346T1/hr unknown
- 2008-10-30 SI SI200831774A patent/SI2217704T1/sl unknown
- 2008-10-30 SI SI200831894T patent/SI2684955T1/en unknown
- 2008-10-30 LT LTEP13179144.4T patent/LT2684955T/lt unknown
- 2008-10-30 HU HUE08844273A patent/HUE031559T2/hu unknown
- 2008-10-30 LT LTEP08844273.6T patent/LT2217704T/lt unknown
- 2008-10-30 ES ES08844273.6T patent/ES2618203T3/es active Active
-
2012
- 2012-08-08 US US13/569,786 patent/US8912158B2/en active Active
-
2014
- 2014-06-05 JP JP2014116545A patent/JP2014196317A/ja active Pending
- 2014-07-31 US US14/448,119 patent/US9279123B2/en active Active
-
2016
- 2016-02-10 US US15/040,487 patent/US9862949B2/en active Active
- 2016-06-24 JP JP2016125260A patent/JP2016199565A/ja active Pending
-
2017
- 2017-02-22 CY CY20171100245T patent/CY1120360T1/el unknown
- 2017-12-04 HR HRP20171874TT patent/HRP20171874T1/hr unknown
- 2017-12-06 CY CY20171101283T patent/CY1120226T1/el unknown
- 2017-12-14 JP JP2017239230A patent/JP2018083817A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE031559T2 (hu) | Eljárás angiogenezis, vaszkularizáció vagy érjavítás elõsegítésére vagy tumor-angiogenezis gátlására | |
| Cai et al. | Diabetic retinopathy: animal models, therapies, and perspectives | |
| Mirotsou et al. | Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair | |
| AU2016244333A1 (en) | DLL3 modulators and methods of use | |
| Fukui et al. | Gene therapy for the inner ear | |
| Tanaka et al. | Modeling alveolar soft part sarcoma unveils novel mechanisms of metastasis | |
| UA119046C2 (uk) | Модулятор фактора в комплемента | |
| US20150307554A1 (en) | Nts-polyplex nanoparticles system for gene therapy of cancer | |
| UA126549C2 (uk) | Композиція і спосіб для з'єднання позаклітинних доменів типу і та типу іі як гетерологічного химерного білка | |
| BR112020012921A2 (pt) | Oligonucleotídeos antissenso de alfa-sinucleína e usos dos mesmos | |
| US9757402B2 (en) | Method for measuring cell-to-cell transmission of α-synuclein aggregates using bimolecular fluorescence complementation system and method for screening a substance for preventing or treating neurodegenerative disease using the same | |
| Kolosov et al. | A role for tricellulin in the regulation of gill epithelium permeability | |
| Xiong et al. | Long non‐coding RNA NORAD aggravates acute myocardial infarction by promoting fibrosis and apoptosis via miR‐577/COBLL1 axis | |
| Ceinos et al. | Mutations in blind cavefish target the light-regulated circadian clock gene, period 2 | |
| Hernandez et al. | Preclinical evaluation of a cell-based gene therapy using the sleeping beauty transposon system in choroidal neovascularization | |
| Zhang et al. | Malignant pericytes expressing GT198 give rise to tumor cells through angiogenesis | |
| Szarka et al. | The role of gap junctions in cell death and neuromodulation in the retina | |
| WO2014123614A2 (en) | Antiviral rift valley fever virus virus peptides and methods of use | |
| Yu et al. | Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression | |
| ES2708624T3 (es) | Composiciones y métodos para tratar la enfermedad arterial periférica | |
| CN101573445A (zh) | 由胰腺腺泡细胞向胰岛素生成细胞的体内转化 | |
| Klein et al. | Neuron navigator 3a regulates liver organogenesis during zebrafish embryogenesis | |
| US20200276312A1 (en) | Elimination of chronic pain by chronic activation of adenosine receptor type A1 in peripheral sensory neurons | |
| Große et al. | Zebrafish Wtx is a negative regulator of Wnt signaling but is dispensable for embryonic development and organ homeostasis | |
| Xu et al. | Schisandrin C prevents regorafenib-induced cardiotoxicity by recovering EPHA2 expression in cardiomyocytes |